Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Enhancer profiling of glioblastoma uncovers core oncogenic dependency and therapeutic opportunity [RNA-seq]

ABSTRACT: Enhancer profiling of glioblastoma uncovers core oncogenic dependency and therapeutic opportunity [RNA-seq]

PROVIDER: PRJNA607792 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR11124400_1.fastq.gz	Fastqsanger.gz
	SRR11124400_2.fastq.gz	Fastqsanger.gz
	SRR11124401_1.fastq.gz	Fastqsanger.gz
	SRR11124401_2.fastq.gz	Fastqsanger.gz
	SRR11124402_1.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 70

Similar Datasets

Enhancer profiling of glioblastoma uncovers core oncogenic dependency and therapeutic opportunity

Project description:Enhancer profiling of glioblastoma uncovers core oncogenic dependency and therapeutic opportunity

| PRJNA607789 | ENA

Enhancer profiling of glioblastoma uncovers core oncogenic dependency and therapeutic opportunity [ChIP-seq]

Project description:Enhancer profiling of glioblastoma uncovers core oncogenic dependency and therapeutic opportunity [ChIP-seq]

| PRJNA607793 | ENA

Enhancer profiling of glioblastoma uncovers core oncogenic dependency and therapeutic opportunity [ChIP-seq]

Project description:Here, by mapping H3K27ac deposition, we analyze the active regulatory landscapes across primary GBM biopsies, normal brain tissues, and cell line counterparts. Analysis of differentially regulated enhancers, especially super-enhancers between GBM and normal brain tissues, as well as among GBM samples with matched RNA-sequencing data, uncovered unrecognized layers of oncogenic core transcriptional dependency and inter-tumor heterogeneity. Moreover, we demonstrate the functional relevance of leading candidates of super-enhancer-driven transcriptional factors, long non-coding RNAs, and druggable targets in GBM. Through profiling of transcriptional enhancers, our integrative study provides clinically relevant insights into GBM molecular classification, pathogenesis, and therapeutic innovations.

2021-05-05 | GSE145644 | GEO

Enhancer profiling of glioblastoma uncovers core oncogenic dependency and therapeutic opportunity [RNA-seq]

2021-05-05 | GSE145645 | GEO

Enhancer profiling of glioblastoma uncovers core oncogenic dependency and therapeutic opportunity

Project description:This SuperSeries is composed of the SubSeries listed below.

2021-05-05 | GSE145646 | GEO

Oncogenic MYC induces a dependency on the spliceosome in human cancer

Project description:c-MYC (MYC) overexpression or hyperactivation is one of the most common drivers of human cancer. Despite intensive study, the MYC oncogene remains recalcitrant to therapeutic inhibition. Like other classic oncogenes, hyperactivation of MYC leads to collateral stresses onto cancer cells, suggesting that tumors harbor unique vulnerabilities arising from oncogenic activation of MYC. Herein, we discover the spliceosome as a new target of oncogenic stress in MYC-driven cancers. We identify BUD31 as a MYC-synthetic lethal gene, and demonstrate that BUD31 is a splicing factor required for the assembly and catalytic activity of the spliceosome. Core spliceosomal factors (SF3B1, U2AF1, and others) associate with BUD31 and are also required to tolerate oncogenic MYC. Notably, MYC hyperactivation induces an increase in total pre-mRNA synthesis, suggesting an increased burden on the core spliceosome to process pre-mRNA. In contrast to normal cells, partial inhibition of the spliceosome in MYC-hyperactivated cells leads to global intron retention, widespread defects in pre-mRNA maturation, and deregulation of many essential cell processes. Importantly, genetic or pharmacologic inhibition of the spliceosome in vivo impairs survival, tumorigenicity, and metastatic proclivity of MYC-dependent breast cancers. Collectively, these data suggest that oncogenic MYC confers a collateral stress on splicing and that components of the spliceosome may be therapeutic entry points for aggressive MYC-driven cancers. Examination of intron rentention in MYC-ER HMECs, in 4 conditions

2015-09-03 | E-GEOD-66182 | biostudies-arrayexpress

Synthetic essentiality between PTEN and core dependency factor PAX7 dictates rhabdomyosarcoma identity

Project description:Synthetic essentiality between PTEN and core dependency factor PAX7 dictates rhabdomyosarcoma identity

| PRJNA702273 | ENA

Oncogenic MYC induces a dependency on the spliceosome in human cancer

2015-09-03 | GSE66182 | GEO

Pluripotency reprogramming by competent and incompetent POU factors uncovers temporal dependency for Oct4 and Sox2

Project description:Pluripotency reprogramming by competent and incompetent POU factors uncovers temporal dependency for Oct4 and Sox2

| PRJNA407838 | ENA

Modeling clonal evolution and oncogenic dependency in vivo in the context of hematopoietic transformation

Project description:Modeling clonal evolution and oncogenic dependency in vivo in the context of hematopoietic transformation

| PRJNA840894 | ENA